News and Announcements

Hikma falls as injectables outlook cut despite strong guidance for branded unit

By Iain Gilbert

Date: Thursday 05 Nov 2026

(Sharecast News) - Drugmaker Hikma Pharmaceuticals trimmed revenue guidance for its injectables division on Thursday, offsetting a more upbeat outlook for its branded business.
Hikma now expects injectables revenue to be broadly flat in 2026, compared with previous guidance for low single-digit growth, although it maintained expectations for a core operating...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page